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Background/Aims: In clinical trials it is not unusual for errors to occur during the process of 
recruiting, randomising and providing treatment to participants. For example, an ineligible 
participant may inadvertently be randomised, a participant may be randomised in the incorrect 
stratum, a participant may be randomised multiple times when only a single randomisation is 
permitted, or the incorrect treatment may inadvertently be issued to a participant at 
randomisation. Such errors have the potential to introduce bias into treatment effect estimates 
and affect the validity of the trial, yet there is little motivation for researchers to report these 
errors and it is unclear how often they occur. The aim of this study is to assess the prevalence of 
recruitment, randomisation and treatment errors and review current approaches for reporting 
these errors in trials published in leading medical journals. 
 
Methods: We conducted a systematic review of individually randomised, phase III, randomised 
controlled trials published in New England Journal of Medicine, Lancet, Journal of the American 
Medical Association, Annals of Internal Medicine and British Medical Journal from January to 
March 2015. The number and type of recruitment, randomisation and treatment errors that were 
reported and how they were handled was recorded. Corresponding authors were contacted for a 
random sample of trials included in the review and asked to provide details on unreported errors 
that occurred during their trial. 
 
Results: We identified 241 potentially eligible articles, of which 82 met the inclusion criteria 
and were included in the review. These trials involved a median of 24 centres and 650 
participants, and 87% involved two treatment arms. Recruitment, randomisation or treatment 
errors were reported in 32/82 trials (39%) that had a median of 8 errors. The most commonly 
reported error was ineligible participants inadvertently being randomised. No mention of 
recruitment, randomisation or treatment errors was found in the remaining 50/82 trials (61%). 
Based on responses from 9 of the 15 corresponding authors who were contacted regarding 
recruitment, randomisation and treatment errors, between 1% and 100% of the errors that 
occurred in their trials were reported in the trial publications. 
 
Conclusions: Recruitment, randomisation and treatment errors are common in individually 
randomised, phase III trials published in leading medical journals but reporting practices are 
inadequate and reporting standards are needed. We recommend researchers report all such errors 
that occurred during the trial and describe how they were handled in trial publications to improve 
transparency in reporting of clinical trials. 
 
Keywords 





Randomisation is the unique and most critical feature of randomised controlled trials (RCTs), 
enabling the formation of similar treatment groups at baseline and an unbiased estimate of the 
treatment effect. In practice, the randomisation process typically involves a series of steps, from 
assessing eligibility and obtaining consent, through to performing the randomisation and 
providing the assigned treatment. Even in well-conducted trials, it is not uncommon for errors to 
occur during this process of recruiting, randomising and providing treatment to participants. For 
example, an ineligible participant may inadvertently be randomised, a participant may be 
randomised in the incorrect stratum, a participant may be randomised multiple times when only a 
single randomisation is permitted, or the incorrect treatment may inadvertently be issued to a 
participant at randomisation. Such errors have the potential to undermine the benefits of 
randomisation, affect the validity of the trial and introduce bias into treatment effect estimates if 
handled incorrectly, yet detailed discussion of these specific errors in the literature remains 
limited.1, 2  
 
When recruitment, randomisation or treatment errors occur, it is important to report their 
existence and describe how they were handled in trial publications, as this allows readers to 
assess the extent of the problem and whether the errors were dealt with appropriately. Guidance 
on handling common recruitment, randomisation and treatment errors has been provided 
previously.1, 2 However, there is little motivation for researchers to report these errors, as they are 
not a requirement in the widely adopted Consolidated Standards of Reporting Trials 
(CONSORT) statement.3, 4 It is unclear how often recruitment, randomisation and treatment 
errors occur in trials and how they are reported in trial publications. The aim of this study is to 
assess the prevalence of recruitment, randomisation and treatment errors and review current 
approaches for reporting these errors in individually randomised, phase III RCTs published in 
leading medical journals. We focus on the adequacy of reporting practices in relation to the 




A systematic review was conducted according to a pre-specified protocol. The review was 
restricted to the five leading medical journals according to their 2014 impact factor (New 
England Journal of Medicine, Lancet, Journal of the American Medical Association, Annals of 
Internal Medicine, British Medical Journal), as reporting quality is expected to be high in these 
journals. All journals publish one issue each week, except for Annals of Internal Medicine which 
is published fortnightly. The search was conducted in PubMed on 1 December 2015 using the 
search terms ("Annals of internal medicine"[Journal] OR "BMJ"[Journal] OR "Lancet"[Journal] 
OR "JAMA"[Journal] OR "The New England journal of medicine"[Journal]) AND (randomized 
controlled trial[pt] OR controlled clinical trial[pt] OR randomized[tiab] OR randomised[tiab] OR 
placebo[tiab] OR clinical trials as topic [mesh: noexp] OR randomly[tiab] OR trial[ti]) AND 
("2015/01/01"[PDat] : "2015/03/31"[PDat]) NOT (animals[mh] NOT humans[mh]). These 
search terms are identical to those specified in the sensitivity and precision-maximising version 
of the Cochrane highly sensitive search strategy for identifying randomised trials in MEDLINE 
(PubMed format)5 with several additions. First, the search term 'randomised[tiab]' was added, as 
the Cochrane strategy only includes the American spelling 'randomized' and some included 
journals use the British spelling. Second, search terms were added for the journals of interest and 
the three month time period (January-March 2015) that was chosen both for feasibility and to 
allow time for the articles to be Medical Subject Heading indexed prior to conducting the search. 
 
Articles were eligible for inclusion in the review if they reported the results of an individually 
randomised, phase III, RCT conducted in humans. Articles were excluded if they indicated they 
reported the results of a pilot, feasibility, phase I, phase II or cluster randomised trial, as these 
trials may substantively differ from individually randomised, phase III trials in their conduct, 
protocol and data monitoring procedures and may therefore have qualitatively different error 
rates. Short reports or articles presenting the results of multiple trials together were also 
excluded, as these have less space to provide details about any errors that occurred. To ensure 
that each trial was included only once in the review, only the first article reporting the primary 
trial results was eligible. 
 
Titles and abstracts of all articles identified in the search were independently assessed for 
potential eligibility by two reviewers (LY and ED). The full text of all potentially eligible articles 
was then examined by LY, with a 20% random sample independently examined by a second 
reviewer (BK or JC), to confirm eligibility and extract trial details for eligible trials using a 
purpose-specific data extraction form. The published articles and supplementary results files 
were included in the review process but not the trial protocols for feasibility. An initial version of 
the data extraction form was piloted by two reviewers (LY and BK) on one article from each 
journal of interest published in 2014. Final changes were made to the form based on discussion 
prior to conducting the full text review. Any disagreements between reviewers were resolved by 
discussion.  
 
For each eligible article, basic trial characteristics were collected, including the number of 
participants, centres and treatment arms, the methods used to generate the randomisation 
sequence and perform the randomisation, and whether participants were allowed to be 
randomised multiple times. In extracting details of the recruitment, randomisation and treatment 
errors that were reported, four specific types of errors that have been discussed in detail 
previously2 were assessed: ineligible participant randomised, participant randomised using 
incorrect baseline information (e.g. participant randomised in incorrect stratum), participant 
incorrectly randomised multiple times, and participant received incorrect treatment. For the latter 
error, all instances of participants receiving the incorrect treatment were documented. Further 
details were recorded, where available, to enable the reviewer to determine whether any 
instances were due to errors rather than deliberate departures from the assigned treatment (non-
compliance), as we were only interested in identifying errors. Free text fields were used to 
document any other errors that occurred during the process of recruiting, randomising and 
providing treatment to participants. Details on each type of error were recorded, including the 
number of errors that occurred, where the errors were reported and any information provided on 
how they were handled during the conduct of the trial or in the analysis. The number and 
percentage of trials reporting each type of error were calculated. The total number and 
prevalence of reported errors were summarised across trials by the median and range. Trials that 
did not mention any errors were excluded from these summaries, as it was unclear whether they 
had zero errors or failed to report the errors that had occurred. Prevalence was expressed as the 
number of errors reported per 10,000 participants randomised, since each participant provides an 
opportunity for an error to occur and there was considerable variation in sample size across trials.  
 
As trial publications may not provide full details of all recruitment, randomisation and treatment 
errors that occurred, a random sample of corresponding authors were contacted to seek 
clarification regarding these errors for their trial. Specifically, we asked (i) whether all errors that 
occurred in the trial were correctly identified by our review, and (ii) for details on the number 
and type of errors not reported in the trial publication and hence not identified by our review. 
Where no response was received, a single follow-up email was sent several weeks later. Only the 
random sample of trials selected for duplicate review that were subsequently found to be eligible 
were included in this process for feasibility. Corresponding authors were advised that responses 




The search strategy identified 241 articles. Based on the title and abstract review, both reviewers 
agreed on whether or not the article should proceed to full text review for 230/241 articles 
(95%). There were 89 articles that underwent a full text review, of which 82 articles (92%) met 
the inclusion criteria and were included in the review (see Supplementary Material). There were 
18/89 articles (20%) randomly selected for duplicate full text review. Both reviewers agreed on 
whether or not the article was eligible for 16/18 articles (89%) and 15/18 articles (83%) met the 
inclusion criteria and were included in the review (Figure 1).  
 
The characteristics of the 82 trials included in the review are presented in Table 1. The majority 
of trials were published in either Lancet (39%) or New England Journal of Medicine (37%). The 
trials varied greatly in size, with a median of 24 centres and 650 participants. Most trials 
involved 2 treatment arms (87%) and had a publicly available protocol (77%). Many trials failed 
to clearly describe the methods used to generate the randomisation sequence (29%) or how the 
randomisation was performed (34%). Where randomisation was clearly described, it was most 
commonly performed using a web-based system (27%) and half the trials used stratified 
permuted blocks to generate the randomisation sequence. Only 12/82 trials (15%) explicitly 
stated that repeat randomisations were not permitted as part of the inclusion/exclusion criteria.  
 
One or more recruitment, randomisation or treatment errors were reported in 32/82 trials (39%) 
that had a median of 8 errors reported (range 1-176) and 906 randomised participants per trial. 
The number of errors reported per 10,000 participants randomised varied greatly across these 32 
trials, ranging from 2 to 934 (median 71). For the remaining 50/82 trials (61%) that included a 
median of 505 randomised participants, we found no mention of any errors and were unable to 
determine whether no errors had occurred or errors had occurred but not been reported. 
 
The specific types of errors reported are summarised in Table 2. There were 23/82 trials (28%) 
reporting that ineligible participants had been inadvertently randomised, with a median of 12 
ineligible participants randomised per trial (range 1-80). This information was typically reported 
in the results section or flow diagram but could also be found in a table or online supplement. 
While few trials explicitly stated how the ineligible participants were handled, it was possible to 
infer that they were excluded from the primary analysis in 12/23 trials (52%), and included in the 
primary analysis in 11/23 trials (48%), based on the flow diagram and statistical methods section. 
Only 2/82 trials (2%) reported that any participants were randomised using incorrect baseline 
information, both of which involved the use of stratified permuted blocks. In one of these trials, 
4 errors were reported in the flow diagram and the affected participants were excluded from the 
primary analysis. In the other trial, 8 errors were reported in the online supplementary material 
and the affected participants were included in the analysis, although it was unclear whether the 
correct or incorrect baseline information was used in the adjusted analysis. No trial reported that 
a participant was randomised multiple times in error. Most of the 82 trials included in the review 
(n=64, 78%) reported that one or more participants failed to receive the allocated treatment 
(median 7 participants per trial) and this information was usually included in the flow diagram. 
However, only 42% (27/64) of these trials provided sufficient detail to determine whether any 
instances were due to errors (n=4 trials) or other reasons, such as participant withdrawal, 
participant non-compliance or treatment provider recommendation (n=23 trials). The number of 
participants who failed to receive the allocated treatment in the 4 trials where it was clearly due 
to an error ranged from 2 to 8 and in each trial the affected participants were included in their 
randomised groups in an intention to treat analysis. There were 9/82 trials (11%) that reported 
other types of errors and these were typically identified from the flow diagram or online 
supplement. The most common other type of error was failure to randomise people who were 
eligible for the trial and had provided consent to participate. 
 
Of the 15/82 trials (18%) included in the review where corresponding authors were contacted 
regarding errors for their trial, responses were received from 9/15 trials (60%) that randomised a 
median of 640 participants. Between 1% and 100% of the errors that had occurred in these trials 
were reported in the trial publications. Two trials provided information on an additional 301 
errors that were not reported in the trial publications: 286 ineligible participants were 
inadvertently randomised, 3 participants were randomised following improper consent 
procedures, 4 participants were possibly given the incorrect treatment at randomisation, 6 
participants were definitely given the incorrect treatment at randomisation, and 2 participants 




Recruitment, randomisation and treatment errors were common in individually randomised, 
phase III RCTs published in leading medical journals in 2015, with 39% (32/82) of trials 
reporting at least one error. While the number of errors reported was fairly small relative to the 
number of participants randomised (median 71 errors per 10,000 participants randomised), we 
believe these errors are both common and important enough to warrant careful consideration 
regarding how they might be prevented, as well as how they should be handled during the 
conduct of the trial and in the analysis when they do occur. Recruitment errors may be reduced 
by use of a dummy enrolment run-in phase.6 Randomisation errors may be minimised by 
thoroughly checking the randomisation sequence and testing the randomisation system prior to 
commencing the trial.1 Methods for handling common recruitment, randomisation and treatment 
errors that maintain the goals of the intention-to-treat principle have been discussed in detail 
elsewhere.2 Such methods should ideally be pre-specified in the trial protocol and this could be 
incorporated in a future SPIRIT statement.7, 8 
 
Estimating the true prevalence of recruitment, randomisation and treatment errors based on 
errors reported in trial publications is challenging. If the 61% (50/82) of trials included in our 
review that did not mention any errors in fact had no errors, then we have overestimated the 
median number of errors per trial. In contrast, if reporting of errors was incomplete then we may 
have underestimated the median. The latter scenario is more likely, given our finding that as little 
as 1% of errors that occur in a trial may be reported. It is difficult to estimate the true rate of 
under-reporting based on this finding due to the small number of corresponding authors 
contacted (15), the moderate response rate (60%), and the possibility that this process did not 
identify all unreported errors. Despite these limitations, our survey of corresponding authors 
remains valuable as it confirms previous speculation that errors occur more often than they are 
reported1 and highlights the inadequacy of current reporting practices. More accurate estimates 
of the prevalence of recruitment, randomisation and treatment errors could be obtained from 
future trial publications if reporting practices improve. 
 
We are aware of one previous review that assessed the prevalence and reporting of recruitment, 
randomisation and treatment errors as part of a broader review of protocol violations.9 Among 80 
cluster or individually randomised trials published in leading medical journals in 2009, 13% of 
trials reported ’enrolment protocol violations’, with a median of 0.8% of participants found to be 
ineligible (or 80 per 10,000 randomised). This error was more common in our review, where 
28% of trials reported that a median of 91 participants per 10,000 randomised were ineligible. 
‘Randomisation protocol violations’ were reported in 9% of trials included in the previous 
review, while only 2% of trials in our review reported that participants were randomised using 
incorrect baseline information. ‘Study intervention protocol violations’ were reported in 21% of 
trials in the previous review, with a median of 1.3% of participants (or 130 per 10,000 
randomised) experiencing ‘a dosing, timing or delivery error in the study intervention 
attributable to members of the research team’. Treatment errors were less common in our review, 
where only 5% of trials reported errors affecting a median of 41 participants per 10,000 
randomised.  Differences in findings between the reviews may reflect changes in reporting 
practices over time or differences in the definitions and methodology used. Our review adds to 
this study by considering any errors that occurred during the process of recruiting, randomising 
and providing treatment to participants, and providing evidence of under-reporting of these 
errors by contacting corresponding authors.  
 
The potential for recruitment, randomisation and treatment errors to impact on the trial results 
depends on the type of error, how often it occurs and how it is handled during the conduct of the 
trial and in the analysis. By far the most commonly reported error found in this review was 
ineligible participants inadvertently being randomised. This is a serious concern, since the trial 
treatments under investigation may be inappropriate or harmful for ineligible participants,2 and 
care must be taken if they are to be excluded from the analysis to avoid potential bias.10-12 
Unfortunately such errors are unavoidable in some scenarios, as participants may appear to be 
eligible based on the information available at the time of randomisation and only later be 
identified as ineligible. Another common but far less concerning reported error was failure to 
randomise people who were eligible for the trial and had provided consent to participate. These 
missed opportunities will lead to increased time required to meet recruitment targets and could 
impact on the generalisability of the trial results but will not bias treatment group comparisons. 
Contrary to our expectations, no trial reported randomising the same participant twice in error in 
the trial publication, although 2 occurrences were identified through contacting authors and we 
have experienced this error in our own trials. These repeat randomisations introduce the 
possibility of choosing the preferred randomised treatment for the participant, which could 
introduce bias. While few instances of using incorrect baseline information to perform the 
randomisation were reported, the implications of these errors can be substantial, particularly for 
dynamic allocation methods such as minimization, as even one error will alter the probability of 
receiving the treatment for future participants.1 Given that balancing variables should be 
controlled for in the analysis,13 these errors raise the question of whether an adjusted analysis 
should be performed using the correct baseline variables or the incorrect versions used to 
perform the randomisation, and this issue is being investigated separately.  
 
Our review highlights several inadequacies in current reporting practices relating to recruitment, 
randomisation and treatment errors. First, many trial reports failed to clearly describe the 
methods used to generate the randomisation sequence and perform the randomisation, making it 
difficult to understand the types of randomisation errors that were possible. This finding is 
surprising, since it is recommended that both the ‘sequence generation’ and ‘allocation 
concealment mechanism’ be fully described in the current CONSORT statement.3, 4 The lack of 
detail on randomisation methods may be explained by the common practice of making trial 
protocols publically available combined with the strict word limits applied by the journals. 
Second, few trials indicated whether repeat participation was permitted in the inclusion/exclusion 
criteria and thus it was often unclear whether a repeat randomisation would be considered an 
error or not. Third, recruitment, randomisation and treatment errors were often poorly reported, 
making it difficult to identify how many errors had occurred (if any). For instance, many trials 
reported that some participants failed to receive the allocated treatment, as recommended in the 
CONSORT flow diagram,3, 4 but insufficient detail was provided to determine whether any cases 
resulted from an error. Fourth, some trials did not report all recruitment, randomisation and 
treatment errors that occurred in the trial publication and hence under-reporting is a concern. 
Finally, it was often challenging to determine how any errors that were reported were handled 
during the conduct of the trial and in the analysis. This is problematic, given the potential for 
bias to be introduced into treatment effect estimates if certain errors are handled incorrectly. 




We make several recommendations for reporting recruitment, randomisation and treatment errors 
in trial publications that could be incorporated into formal reporting standards in future. Our 
recommendations are based on the findings of this review and the collective trial experience of 
the authorship team that has been obtained from serving as trial statisticians, investigators and 
members of independent data monitoring committees involved mainly with publicly funded 
randomised trials in health-related disciplines. Consistent with the CONSORT statement,3, 4 our 
recommendations focus on promoting transparency in reporting, rather than how errors should be 
handled. Specifically, we recommend the following: 
 
1. Fully describe the method of randomisation by following the reporting recommendations 
in the CONSORT statement.3, 4 
2. Indicate whether repeat participation in the trial was permitted in the inclusion/exclusion 
criteria. 
3. Report the number and type of recruitment, randomisation and treatment errors that 
occurred during the trial by treatment group (where applicable), or state that no errors 
were identified. 
4. Provide details on how the errors were handled during the conduct of the trial and in the 
analysis.  
 
The best location in a trial manuscript to report on recruitment, randomisation and treatment 
errors is open to debate. For trials with few errors that are easily described, these could be 
included in the participant flow diagram with additional details provided in footnotes. For trials 
where a range of errors occurred, these may best be reported in a table. Given the strict word 
limits applied by many journals and the increasing use of online supplements, we suggest 
including such a table in a supplementary results file. An example of such a table is given for a 
hypothetical trial in Table 3. While the approaches used to handle the errors during the conduct 
of the trial and in the analysis in this hypothetical trial were chosen to minimise the potential for 
bias to be introduced into the treatment group comparisons, alternative approaches may also be 
appropriate.1, 2 
 
Strengths and limitations 
 
A key strength of this review is that, to our knowledge, it provides the first specific assessment 
of the prevalence of recruitment, randomisation and treatment errors and how they are reported 
in trial publications. By contacting a random sample of corresponding authors, we also provide 
the first formal evidence of under-reporting of these errors in trial publications. A limitation is 
that we did not review additional trial resources such as trial registrations, protocols or other 
publications reporting trial results, both for feasibility and since many readers would only access 
the main trial publication. Review of such additional documents may have provided further 
details on the randomisation methods, inclusion/exclusion criteria and any errors that occurred. A 
further limitation is that our assessment of the prevalence of errors and current reporting 
practices was based on 82 individually randomised, phase III RCTs published in leading medical 
journals, which are unlikely to be representative of all published RCTs. Likewise, our evidence 
of under-reporting of errors was based on responses received from authors of only a small 
sample of trials. Although the contacted trials were chosen at random and should therefore be 
representative of all trials included in the review, a larger study would provide a more accurate 




Recruitment, randomisation and treatment errors are an important and common problem that has 
largely been overlooked in the clinical trials literature. Researchers should be aware of the 
possibility of these errors when designing their trials and give careful consideration to how these 
errors can be minimised and how they should be handled during the conduct of the trial, in the 
analysis and at the reporting stage. Our review indicates that reporting of recruitment, 
randomisation and treatment errors is currently inadequate in individually randomised, phase III 
RCTs published in leading medical journals and reporting standards are needed. Our 
recommendations for reporting these errors could be incorporated in a future update of the 
CONSORT statement to encourage better planning for and clearer and more complete reporting 
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Figure 1: Flow diagram 
 
 
Articles included in the 
review (n=82) 
- duplicate review and author 
contact (n=15) 
Full text articles assessed for 
eligibility (n=89) 
- duplicate review (n=18) 
 
Articles identified in 
PubMed search (n=241) 
Articles excluded during title and abstract 
review (n=152) 
- not an RCT (n=107) 
- not a full report (n=7)  
- pilot/feasibility/phase 1/phase II trial (n=13) 
- multiple trials (n=1) 
- cluster randomised trial (n=10) 
- secondary article (n=14) 
Full text articles excluded (n=7) 
- pilot/feasibility/phase 1/phase II trial (n=5) 
- cluster randomised trial (n=1) 
- secondary article (n=1) 
 
 
Table 1: Characteristics of included trials 
 
Characteristic Summarya (n=82 trials) 
Journal  
    Lancet 32 (39) 
    New England Journal of Medicine 30 (37) 
    Journal of the American Medical Association 10 (12) 
    Annals of Internal Medicine 5 (6) 
    British Medical Journal 5 (6) 
Number of participants: median (range) 650 (40-84496) 
Number of centres: median (range)b 24 (1-1161) 
Number of treatment arms  
    2 71 (87) 
    3 6 (7) 
    ≥4 5 (6) 
Randomisation process  
    Web-based 22 (27) 
    Telephone-based 11 (13) 
    Web-based or telephone-based 8 (10) 
    Sealed envelopes 7 (9) 
    Otherc 6 (7) 
    Unclear 28 (34) 
Randomisation method  
    Unstratified permuted blocks 6 (7) 
    Stratified permuted blocks 41 (50) 
    Minimisation 5 (6) 
    Otherd 6 (7) 
    Uncleare 24 (29) 
Repeat randomisations allowed  
    No 12 (15) 
    Unclear 70 (85) 
Protocol publically available 63 (77) 
 
a Values are number (percentage) unless otherwise indicated. 
b Excludes 5 trials where the number of centres was not stated. 
c Includes 3 trials with technology-based randomisation processes (pager, fax, email) and 3 trials 
with physical randomisation processes (opening next available treatment pack). 
d Includes 2 trials using biased coin randomisation and 4 trials using a combination of 
stratification and minimisation. 
e Includes 18 trials where randomisation was stratified but blocking was not mentioned. 






















Ineligible participant randomised 23 (28) 12 (1-80) 91 (9-934) 
Participant randomised using incorrect baseline 
information 
2 (2)b 6 (4-8) 164 (78-250) 
Participant incorrectly randomised multiple times 0 (0) N/A N/A 
Participant received incorrect treatmentc 4 (5) 6 (2-8) 41 (21-41) 
Other errors: 9 (11) 2 (1-176) 28 (2-877) 
- eligible participant not randomised due to 
randomisation system being unavailable 
1 (1) 7 28 
- participant received study product before being 
randomised 
1 (1) 2 2 
- participant received study product but was never 
randomised 
1 (1) 2 9 
- eligible person consented but was not randomised 1 (1) 176 877 
- participant randomised following improper 
consent procedures 
2 (2) 1 (1-1) 30 (28-32) 
- randomised participant included in subgroup 
undergoing further randomisation without meeting 
eligibility criteria for subgroup 
1 (1) 11 27 
- participant randomised in error without further 
details provided regarding the nature of the error 
2 (2) 6 (2-10) 40 (28-51) 
 
a  Calculated across trials where error was reported. Range not presented for errors reported in 
only one trial. 
b Both trials used stratified permuted blocks. 
c Excludes cases where participant received incorrect treatment due to a deliberate departure 
from the assigned treatment or where the reason was unclear. 
Table 3: Example report of recruitment, randomisation and treatment errors for 
hypothetical trial 
 
Error Number of 
Participants Affected 
How Error Was Handled 
Ineligible participant 
randomised 
6 (4 intervention, 2 
control) 
Treatment was ceased when the ineligibility 
was discovered. Outcome data were collected 
and participants were included in the intention 




4 (2 intervention, 2 
control) 
Participants were included in the intention to 
treat analysis. In the analysis adjusting for the 
stratification variables, participants were 




1 (0 intervention, 1 
control) 
Participant was treated and analysed according 
the first randomisation. The second 
randomisation was excluded from the analysis 




2 (2 intervention, 0 
control) 
Participants remained on the incorrect 
treatment for the duration of the trial. 
Participants were included in their randomised 
group in the intention to treat analysis and in 
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